• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    MORINGA ACQUISITION CORP ANNOUNCES CONTRIBUTION TO TRUST ACCOUNT IN CONNECTION WITH PROPOSED EXTENSION

    8/15/23 9:25:00 AM ET
    $MACA
    Blank Checks
    Finance
    Get the next $MACA alert in real time by email

    New York, NY, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Moringa Acquisition Corp (NASDAQ:MACA) ("Moringa" or the "Company") announced today that, in connection with its previously announced extraordinary general meeting in lieu of the 2023 annual general meeting of shareholders of the Company to be held at 9:00 a.m. Eastern Time/4:00 p.m. local (Israel) time on August 16, 2023 (the "Extraordinary Meeting") for the purpose of considering and voting on, among other proposals, a proposal to extend the date by which the Company must consummate an initial business combination (the "Extension") from August 19, 2023 (the "Current Termination Date") to August 19, 2024 or such earlier date as may be determined by the Company's board of directors, in its sole discretion (such new termination date, the "Extension Date"), the Company's sponsor, Moringa Sponsor, L.P., and/or its wholly-owned subsidiary Moringa Sponsor (US) L.P. (collectively, the "Sponsor"), or the Sponsor's designees, will make additional contributions to the Company's trust account following the approval and implementation of the Extension.

    If the requisite shareholder proposals are approved at the Extraordinary Meeting and the Extension is implemented, the Sponsor or its designees will deposit into the Company's trust account as a loan (a "Contribution", and the Sponsor or its designee making such Contribution, a "Contributor"), on the Current Termination Date, and the 19th day of each subsequent calendar month until, but excluding, the Extension Date, the lesser of (x) $15,000 and (y) $0.025 per public share multiplied by the number of public shares outstanding on such applicable date (each date on which a Contribution is to be deposited into the trust account, a "Contribution Date").

    The Company has not asked the Sponsor to reserve for, nor has the Company independently verified whether the Sponsor will have sufficient funds to satisfy, any such Contributions. If a Contributor fails to make a Contribution by an applicable Contribution Date, the Company will liquidate and dissolve as soon as practicable after such date and in accordance with the Company's Amended and Restated Memorandum and Articles of Association, as amended. The Contributions will be evidenced by a non-interest bearing, unsecured promissory note and will be repayable by the Company upon consummation of an initial business combination. If the Company does not consummate an initial business combination by the Extension Date, any such promissory notes will be repaid only from funds held outside of the trust account or will be forfeited, eliminated or otherwise forgiven. Any Contribution is conditioned on the approval of the requisite shareholder proposals at the Extraordinary Meeting and the implementation of the Extension. No Contribution will occur if such proposals are not approved or the Extension is not implemented. If the Company has consummated an initial business combination or announced its intention to commence winding up prior to any Contribution Date, any obligation to make Contributions will terminate.

    The Company expects that the proceeds held in the trust account will continue to be invested in United States government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended, as determined by the Company, or in an interest bearing demand deposit account, until the earlier of: (i) the completion of the Company's initial business combination, or (ii) the liquidation, and distribution of the proceeds from, the trust account.

    Further information related to attendance, voting and the proposals to be considered and voted on at the Extraordinary Meeting is described in the definitive proxy statement related to the Extraordinary Meeting filed by the Company with the Securities and Exchange Commission (the "SEC") on July 26, 2023 (the "Definitive Proxy Statement"), as supplemented by Moringa's supplemental notification regarding the Extraordinary Meeting filed with the SEC under cover of Schedule 14A on August 10, 2023 (the "Supplement").

    About Moringa Acquisition Corp

    Moringa Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company is led by Ilan Levin, Chairman and CEO of the Company, and Gil Maman, Chief Financial Officer of the Company.

    Forward Looking Statements

    This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Certain of these forward-looking statements can be identified by the use of words such as "believes," "expects," "intends," "plans," "estimates," "assumes," "may," "should," "will," "seeks," or other similar expressions. Such statements may include, but are not limited to, statements regarding the approval of certain shareholder proposals at the Extraordinary Meeting, the implementation of the Extension or any Contributions to the trust account. These statements are based on current expectations on the date of this press release and involve a number of risks and uncertainties that may cause actual results to differ significantly, including those risks set forth in the Definitive Proxy Statement, the Company's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and other documents filed with the SEC. Copies of such filings are available on the SEC's website at www.sec.gov. The Company does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise. Readers are cautioned not to put undue reliance on forward-looking statements.

    Additional Information and Where to Find It

    The Definitive Proxy Statement has been mailed to the Company's shareholders of record as of the record date for the Extraordinary Meeting. Investors and security holders of the Company are advised to read the Definitive Proxy Statement, as supplemented by the Supplement, because it contains important information about the Extraordinary Meeting and the Company. Investors and security holders of the Company may also obtain a copy of the Definitive Proxy Statement, as well as other relevant documents that have been or will be filed by the Company with the SEC, without charge and once available, at the SEC's website at www.sec.gov or by directing a request to: Advantage Proxy, Inc., P.O. Box 13581, Des Moines, WA 98198; Telephone—Toll Free: (877) 870-8565; Collect: (206) 870-8565; Email: [email protected].

    Participants in the Solicitation

    The Company and certain of its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from the Company's shareholders in respect of the proposals to be considered and voted on at the Extraordinary Meeting. Information concerning the interests of the directors and executive officers of the Company is set forth in the Definitive Proxy Statement, which may be obtained free of charge from the sources indicated above.

    Contacts

    Gil Maman, Moringa Acquisition Corp– [email protected]



    Primary Logo

    Get the next $MACA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MACA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MACA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

      Report covers Silexion Therapeutics (NASDAQ:SLXN), a disruptive player in the precision oncology space, developing innovative RNAi therapies targeting KRAS-driven cancers, highlighting the company's impressive clinical achievements and unique approach alongside industry drivers including the increasing M&A activity in the space Silexion Therapeutics (NASDAQ:SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference (RNAi) therapies for KRAS-driven cancers. As a recently de-SPACed company following its merger with Moringa Acquisition Corp (NASDAQ:MACA), Silexion presents an interesting opportunity in the rap

      9/9/24 7:32:00 AM ET
      $MACA
      $SLXN
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

      MODI'IN, Israel and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Ltd. ("Silexion"), a clinical-stage, oncology-focused biotechnology company and Moringa Acquisition Corp (NASDAQ:MACA) ("Moringa"), a publicly-traded special purpose acquisition company, today announced the completion of their previously announced business combination (the "Business Combination") with Biomotion Sciences (the "combined company"), a recently formed entity. The combined company's name is changing from Biomotion Sciences to "Silexion Therapeutics Corp", and its ordinary shares and warrants are expected to begin trading on Nasdaq under the tickers "SLXN" and "SLXNW", respectively, on August 16

      8/15/24 4:05:00 PM ET
      $MACA
      Blank Checks
      Finance
    • Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp

                                             Silexion's first generation product, Loder™, successfully tested in a multinational Phase 2a clinical trial in patients with non-resectable pancreatic cancer which harbors an oncogene believed to be a major driver of the cancer In combination with chemotherapy, Loder resulted in a median overall survival (OS) advantage of 9.3 months over chemotherapy alone (22.7 vs 13.4 months) Modi'in, Israel and New York, New York, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Moringa Acquisition Corp (NASDAQ:MACA) ("Moringa"), a special purpose acquisition company, today announced it has entered into a business combination agreement with Silexion Ltd. ("Silexion"), a cli

      2/22/24 8:27:00 AM ET
      $MACA
      Blank Checks
      Finance

    $MACA
    Leadership Updates

    Live Leadership Updates

    See more
    • Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors

      JERUSALEM, March 21, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately. "We are pleased to welcome Ruti as the newest member of our Board of Directors," said Uzi Sofer, Chief Executive Officer and Chairman of Alpha Tau. "Ruti's extensive knowledge and experience advising healthcare companies through financial and strategic operations will be a tremendous asset to the Company. We are eager to have her on board and benefit from her insights into our corporate and clinical plan as we grow the Company." Ruti

      3/21/22 4:05:00 PM ET
      $DRTS
      $MACA
      $VBLT
      Medical/Dental Instruments
      Health Care
      Blank Checks
      Finance

    $MACA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)

      SC 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      2/14/24 6:28:12 AM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)

      SC 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      2/12/24 4:24:57 PM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)

      SC 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      2/8/24 1:16:56 PM ET
      $MACA
      Blank Checks
      Finance

    $MACA
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Moringa Acquisition Corp

      SCHEDULE 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      8/27/24 11:00:41 AM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form 15-12G filed by Moringa Acquisition Corp

      15-12G - Moringa Acquisition Corp (0001835416) (Filer)

      8/26/24 9:49:09 AM ET
      $MACA
      Blank Checks
      Finance
    • Moringa Acquisition Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - Moringa Acquisition Corp (0001835416) (Filer)

      8/21/24 4:05:08 PM ET
      $MACA
      Blank Checks
      Finance

    $MACA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Hudson Bay Capital Management Lp disposed of $4,253,473 worth of Class A Ordinary Shares (401,271 units at $10.60)

      4 - Moringa Acquisition Corp (0001835416) (Issuer)

      8/24/23 2:31:41 PM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form 3: New insider Hudson Bay Capital Management Lp claimed ownership of 401,271 units of Class A Ordinary Shares

      3 - Moringa Acquisition Corp (0001835416) (Issuer)

      4/5/23 4:59:51 PM ET
      $MACA
      Blank Checks
      Finance